Compugen Cuts Q3 Loss

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Compugen today reported that it had cut its net loss around 16 percent for the third-quarter, while the firm brought in no revenues for the period.

The Tel Aviv, Israel-based drug discovery informatics and drug development firm posted a net loss of $1.6 million, or $.05 per share, for the three-month period ended Sept. 30, compared to a net loss of $1.9 million, or $.06 per share, for the third quarter of 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Researchers report that while host genetics influence the oral microbiome, they don't appear to affect cavity-causing microbes, the Economist says.

Pandas' gut microbiomes change as what they eat changes with the seasons, writes Discover's Inkfish blog.

In PLOS this week: comparative genomic study of malaria-linked macaque parasite, search for apple root reference genes, and more.